Related Experiment Video

Updated: Feb 1, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran

Mehdi Mohammadzadeh1,2, Hamid Derafshi3,4, Tayebeh Ghari2,5

  • 1Dept. of Pharmacoeconomy and Administrative Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Iranian Journal of Public Health
|December 8, 2018
PubMed

Insights

Hepatitis C Virus (HCV) infection significantly impacts liver health and incurs substantial economic costs. This study reveals that HCV

Area of Science:

  • Hepatology
  • Public Health
  • Health Economics

Background:

  • Hepatitis C Virus (HCV) infection is a leading cause of liver disease, mortality, and morbidity.
  • HCV contributes to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
  • This autoimmune liver disease presents a significant economic burden.

Purpose of the Study:

  • To estimate the economic and social burden of Hepatitis C Virus (HCV) infection in Iran.
  • Quantify direct and indirect costs associated with HCV.
  • Assess the impact on disability-adjusted life years (DALYs) and social welfare.

Main Methods:

  • A cohort of 200 HCV patients from Tehran, Karaj, and Tabriz, Iran, were enrolled in 2015.
  • Direct and indirect costs were calculated to determine the overall economic burden.
  • DALYs and social welfare impacts were estimated.

Main Results:

  • The total economic burden of HCV infection was estimated at 26,242.8 purchasing power parity (PPP$).
  • Intangible costs associated with HCV were calculated to be 207,421.6 PPP$.
  • Direct costs per patient exceed average household consumption expenditure.

Conclusions:

  • HCV infection imposes a substantial financial strain on patients.
  • Implementing policies to control HCV and enhance insurance coverage is recommended.
  • Reducing patient costs should be a public health priority.
Abstract

Keywords:
DALYsDirect and indirect costsEconomic burden of diseaseHepatitis CIran

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
128.1K
What are Estimates?01:06

What are Estimates?

It isn't easy to measure a parameter such as the mean height or the mean weight of a population. So, we draw samples from the population and calculate the mean height or mean weight of the individuals in the sample. This sample data acts as a representative measure of the population parameter. These sample statistics are known as estimates. 
The estimate for the mean of a sample is denoted by ͞x, whereas the mean of the population is designated as μ. Further, parameters such...
8.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247